TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03228667
Drug: N-803 + Atezolizumab + PD-L1 t-haNK
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
Study: NCT03228667
Drug: N-803 + Avelumab + PD-L1 t-haNK
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
Study: NCT03514108
Drug: Hydralazine Isosorbide Dinitrate
Normalized name: hydralazine / isosorbide dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
Study: NCT03228667
Drug: N-803 + Durvalumab + PD-L1 t-haNK
Normalized name: PD-L1/4-1BB bispecific antibody
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
Study: NCT03228667
Drug: N-803 + Docetaxel + Pembrolizumab
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).
Study: NCT03228667
Drug: N-803 + Docetaxel + Nivolumab
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
Study: NCT06771271
Drug: RO7200220
Normalized name: RO7200220
DrugBank: RO7200220 (DB18437)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7200220 was administered as IVT injection.
Study: NCT06771271
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab was administered as IVT injection.
Study: NCT01515527
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.
Study: NCT01515527
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.
Study: NCT01515527
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
Study: NCT03514108
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Study: NCT03639779
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
Study: NCT04235036
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
Study: NCT04235036
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
Study: NCT02676375
Drug: Combination Bupropion + NRTs
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02676375
Drug: Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03961568
Drug: Cenobamate
Normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: active drug
Study: NCT03773965
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT04052555
Drug: Berzosertib
Normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03789110
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
Study: NCT03789110
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Study: NCT04151680
Drug: Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive intermittent treatment with a novel oral anticoagulant drug
Study: NCT04151680
Drug: Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive chronic treatment with a novel oral anticoagulant drug
Study: NCT02597829
Drug: Certolizumab Pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection
Study: NCT00877591
Drug: Fosamprenavir/Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1400/200 mg once daily for 15 days total
Study: NCT00877591
Drug: Darunavir/Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 800/100 mg once daily for 15 days total
Study: NCT00877591
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg once daily for 15 days total
Study: NCT00877591
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg once daily for 15 days total
Study: NCT03986034
Drug: During Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
Study: NCT03514017
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
Study: NCT03514017
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
Study: NCT02145546
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
Study: NCT02145546
Drug: Propafenone
Normalized name: Propafenone
DrugBank: Propafenone (DB01182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg per 8 hours, 3 times per day
Study: NCT02145546
Drug: Sotalol
Normalized name: Sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg twice per day.
Study: NCT00177554
Drug: Chemotherapy and Radioimmunotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CHOP-R x 3 cycles followed by zevalin and extended rituximab
Study: NCT00651664
Drug: alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (MLN8237) capsules
Study: NCT04454866
Drug: Continuous infusion of penehyclidine
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study: NCT03343704
Drug: Idarucizumab
Normalized name: Idarucizumab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT02307682
Drug: Brolucizumab ophthalmic solution
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ophthalmic solution for IVT injection
Study: NCT02307682
Drug: Aflibercept ophthalmic solution
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ophthalmic solution for IVT injection
Study: NCT00877591
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days
Study: NCT03206203
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein
Study: NCT03206203
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein
Study: NCT01371331
Drug: Tacrolimus granules
Normalized name: tacrolimus Granules for Oral Suspension
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02017340
Drug: Nilvadipine
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg of Nilvadipine taken once a day at lunch time for 78 weeks
Study: NCT03602118
Drug: Phenobarbital Sodium Injection
Normalized name: Phenobarbital Sodium Injection
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
Study: NCT00951483
Drug: Quetiapine-XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
Study: NCT00930293
Drug: Citalopram hydrobromide
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
Study: NCT05141669
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants who initiated fingolimod to treat multiple sclerosis (MS)
Study: NCT03565887
Drug: RVL-1201
Normalized name: ALLANTOIN 5 g in 100 mL TOPICAL CREAM [RVLAIM SILICONE SCAR Cream]
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RVL-1201 ophthalmic solution 0.1%
Study: NCT01688700
Drug: Nimotuzumab combined with paclitaxel and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy.
Study: NCT02014714
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
Study: NCT00329069
Drug: atorvastatin (drug)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01542918
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral
Study: NCT01542918
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)
Study: NCT00259051
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04560998
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
Study: NCT02325492
Drug: Aramchol
Normalized name: Aramchol
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03809481
Drug: Danaparoid Sodium
Normalized name: Danaparoid Sodium
DrugBank: Danaparoid (DB06754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
Study: NCT03809481
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic direct thrombin inhibitor
Study: NCT06535048
Drug: Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks.
Study: NCT02154763
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00088231
Drug: Imatinib Mesylate (Gleevec)
Normalized name: imatinib Oral Tablet [Gleevec]
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle.
Study: NCT00088231
Drug: PTK 787 (vatalanib)
Normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle.
Study: NCT01311960
Drug: bevacizumab eye drop 0.05%
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
Study: NCT01538381
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib for 2 weeks at a dose of 40 mg/day
Study: NCT02654626
Drug: KBP-7072
Normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Intervention
Study: NCT00739349
Drug: NOVA22007 ''Cyclosporine''
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05% Ophthalmic Cationic Emulsions
Study: NCT00739349
Drug: NOVA22007 ''Cyclosporine''
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.1% Ophthalmic Cationic Emulsions
Study: NCT01986465
Drug: Depomedrol
Normalized name: epomediol
DrugBank: Epomediol (DB13802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01683864
Drug: positive cytology with HIPEC
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIPEC with mytomycin and cisplatin
Study: NCT03820817
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02037412
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
Study: NCT02037412
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
Study: NCT00867217
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects received letrozole as standard of care.
Study: NCT01988779
Drug: oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01988779
Drug: nebulized levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01298128
Drug: NuvaRing
Normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NuvaRIng 21 days for IVF pre-treatment.
Study: NCT01298128
Drug: marvelon
Normalized name: isopropyl alcohol
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: marvelon 21 daily
Study: NCT01064232
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone Tablets 1 mg
Study: NCT03505905
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
Study: NCT03221426
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03221426
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT03221426
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03221426
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT03531645
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days.
Study: NCT03531645
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days.
Study: NCT00419263
Drug: Peramivir 150 mg
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
Study: NCT00419263
Drug: Peramivir 300 mg
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
Study: NCT01511848
Drug: DFP (ferriprox) and deferasirox (ICL 670)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670
Study: NCT04395105
Drug: High-Dose Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10